Anti-Human IL-13 (Tralokinumab) - 100 mg

All|Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

IL-13 is an important mediator of allergic inflammation and disease1 that plays a role in theregulation of IgE synthesis, induction of adhesion molecules, and chemokine expression2. Thefunctions of IL-13 overlap considerably with those of IL-41. IL-13 induces its effects through amulti-subunit receptor composed of the alpha chain of the IL-4 receptor (IL-4Rα) and an IL-13binding subunit IL-13Rα1. IL-13 induces many features of allergic lung disease, includingairway hyper-responsiveness, goblet cell metaplasia, and mucus hypersecretion, which allcontribute to airway obstruction. IL-13 is also associated with the induction of chronicpulmonary eosinophilia and eosinophilic esophagitis3 and plays a key role in the pathogenesis ofatopic dermatitis4. Although IL-13 is associated primarily with the induction of airway disease, it also has anti-inflammatory properties1. CAT-354 (Tralokinumab) was isolated and optimized using antibody display technologies3.Tralokinumab acts as a neutralizing antibody2 that binds specifically and with high affinity to IL-13, preventing interaction with the IL-13 receptor4. In mice administered human IL-13, tralokinumab blocks human IL-13-induced lung eosinophilia, significantly decreases airwayhyper-responsiveness, and inhibits eosinophil recruitment to the esophagus3. Tralokinumab doesnot affect human IL-13-induced goblet cell metaplasia in mouse lungs. Additionally, phase 3trials produced inconsistent benefits for the treatment of asthma and clinical evaluation wasdiscontinued for this indication4. Tralokinumab has been studied and approved for use in atopic dermatitis4.

≥ 5.0 mg/ml

IL-13 is a cytokine secreted by many cell types but especially T helpertype 2 (Th2) cells.